araag2/HINT huggingface dataset:
Clinical trial NCT01017575 (phase 2, status: completed)
Conditions: hepatitis c infection
ICD codes: B17.0
Drugs: daclatasvir, daclatasvir, placebo, peginterferon alfa-2a, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Subjects chronically infected with hepatitis C virus (HCV) genotype 1

          -  HCV RNA viral load ≥ 10*5* IU/mL (100,000 IU/mL) at screening

          -  The current standard of care naïve or non-responder

        Key Exclusion Criteria:

          -  Cirrhosis

          -  HCC

          -  Co-infection with hepatitis B virus (HBV), HIV-1 or HIV-2
Clinical trial NCT01153763 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: gsk2118436
SMILES: CC(C)(C)C1=NC(=C(S1)C1=NC(N)=NC=C1)C1=C(F)C(NS(=O)(=O)C2=C(F)C=CC=C2F)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Must be at least 18 years of age

          -  Must have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is
             BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF
             mutation assay.

          -  Is treatment naive or has received prior treatment for metastatic melanoma.

          -  Must have measurable disease according to Response Evaluation Criteria in Solid Tumors
             (RECIST 1.1).

          -  Women of child-bearing potential must have a negative pregnancy test within 14 days
             prior to the first dose of study treatment.

          -  Women with reproductive potential must be willing to practice acceptable methods of
             birth control during the study and for up to 4 weeks after the last dose of study
             medication.

          -  Men with reproductive potential must be willing to practice acceptable methods of
             birth control during the study and for up to 16 weeks after the last dose of study
             medication.

          -  Must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

          -  Adequate organ function.

        Exclusion Criteria:

          -  Previous treatment with a BRAF or MEK inhibitor.

          -  Cancer therapy (chemotherapy with delayed toxicity, radiation therapy, immunotherapy,
             biologic therapy, or major surgery) within the last 3 weeks; chemotherapy regimens
             without delayed toxicity within the last 2 weeks; or use of any investigational
             anti-cancer or other drug within 28 days or 5 half-lives, whichever is longer,
             preceding the first dose of GSK2118436.

          -  A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or
             Hepatitis C Virus (HCV) infection.

          -  History or evidence of brain metastases on MRI or head CT if MRI is not able to be
             performed.

          -  History of other malignancy. Subjects who have been disease-free for 5 years, or
             subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible.

          -  Certain cardiac abnormalities.
Clinical trial NCT00243230 (phase 2, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: vicriviroc maleate 20 mg, vicriviroc maleate 30 mg, placebo
SMILES: COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F, COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)C1=C(C)N=CN=C1C)C1=CC=C(C=C1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects with documented HIV infection with no detectable CXCR4

          -  Prior therapy for >=3 months with >=3 classes of currently marketed (US FDA-approved)
             antiretroviral agents (NRTIs, NNRTIs, PIs, or fusion inhibitors) at any time prior to
             screening

          -  HIV RNA >=1000 copies/mL on a stable ART regimen for >= 6 weeks prior to Screening and
             >=8 weeks prior to randomization

          -  >=1 genotypically documented resistance mutation to a reverse transcriptase (RT)
             inhibitor and >=1 primary resistance mutation to a PI

          -  Acceptable hematologic, renal and hepatic laboratory parameters

        Exclusion Criteria:

          -  No history of previous malignancy (with the exceptions of cutaneous Kaposi's Sarcoma
             without visceral or mucosal involvement that resolved with HAART but without systemic
             anti-cancer treatment, and basal-cell carcinoma of skin surgically resected with
             disease-free margins on pathology exam)

          -  Treatment with cytotoxic cancer chemotherapy,

          -  Recurrent seizure, or CNS condition or drug use predisposing to seizure in the opinion
             of the investigator

          -  No active AIDS-defining opportunistic infection
Clinical trial NCT01151215 (phase 2, status: terminated)
Conditions: neoplasms, breast neoplasms, breast cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: azd8931, anastrozole, placebo
SMILES: CNC(=O)CN1CCC(CC1)OC1=C(OC)C=C2N=CN=C(NC3=CC=CC(Cl)=C3F)C2=C1, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients that have locally advanced or metastatic breast cancer. Lesions should not be
             amenable to surgery or radiation of curative intent

          -  Hormone therapy-naive

          -  Estimated life expectancy of more than 12 weeks

        Exclusion Criteria:

          -  Last dose of prior anti-cancer therapy received within 14 days (or longer if required)

          -  Any eye injury or corneal surgery within 3 months prior to receiving first dose of
             study drug.

          -  Currently receiving (and unwilling to discontinue) oestrogen replacement therapy.
             (last dose <7 days prior to randomisation)
Clinical trial NCT00528580 (phase 2, status: terminated)
Conditions: sepsis
ICD codes: A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7
Drugs: simvastatin, identical-appearing placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    inadequate recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age > 18 years

          -  Initial presentation to the Emergency Department or University of Chicago MD
             office/Dialysis Center for current hospital admission

          -  Sepsis (ACCP/SCCM criteria)

               1. Clinically suspected infection as per the treating physician or confirmed
                  infection

               2. 2 or more of the following: Temperature 38ºC (100.4ºF)or 36ºC (96.8ºF), Heart
                  rate (HR) > 90/min, Respiratory rate (RR) > 20/min or PaCO2 < 32 mmHg, White
                  blood cell count > 12,000/mm3 or < 4000/m3 or > 10%immature neutrophils

          -  Initiation of antibiotics by treating physician for sepsis

          -  Hospitalized from the Emergency Department or University of Chicago MD office/Dialysis
             Center to an inpatient medical service (intensive care unit (ICU)or non-ICU service)
             OR admission to the medical ICU (MICU) from a non-ICU inpatient medical floor.

          -  Assent of the primary treating physician at the time of enrollment.

          -  The meeting of SIRS criteria is due to an infection as per the treating physician.

        Exclusion Criteria:

          -  Pregnancy

          -  ALT >3 times above the upper limit of normal

          -  Elevated creatine phosphokinase (CPK) (>3 times the upper limit of normal)

          -  Concurrent treatment with any of the following drugs: daptomycin, fenofibrate,
             ketoconazole,triaconazole, amiodarone, clarithromycin, cyclosporine,
             erythromycin,nefazodone, niacin, protease inhibitors, telithromycin,
             verapamil,danazol, gemfibrozil

          -  History of allergy or intolerance to statins

          -  Greater than 16 hours after meeting inclusion criteria

          -  Use of 1 more doses of statins in the previous 4 weeks

          -  Clinical indication for treatment with statin during hospital admission (per treating
             physician)

          -  Sufficiently poor prognosis prior to enrollment that treating physicians have elected
             to employ comfort care or plan to discharge to hospice

          -  Transfer from surgical service to medical service

          -  Needing transfusion for either active bleeding or severe hemolysis.
Clinical trial NCT00048204 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: gw597599b, paroxetine
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients meet the diagnosis of Major Depressive Disorder (MDD).

        Exclusion Criteria:

          -  Patients with a primary diagnosis other than MDD.

          -  Patients with a history of schizophrenia, schizoaffective disorders, seizure disorders
             or bipolar affective disorder.

          -  Patients receiving formal psychotherapy or cognitive/behavioral therapy concurrently
             or in the 12 weeks prior to screening visit.

          -  Patient is actively suicidal.

          -  Patients who have a history of migraine headaches.
Clinical trial NCT01665352 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ttp054, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes mellitus

          -  On a stable (for the last 3 months) regimen of either metformin alone or metformin in
             combination with one additional acceptable oral antidiabetic (OAD) agent

          -  HbA1c: Metformin only: 7.0 - 11.0%; Metformin + acceptable OAD agent: 6.5 - 9.5%

        Exclusion Criteria:

          -  History or evidence of significant diabetic complications

          -  History of heart attack, stroke or congestive heart failure

          -  Severe, uncontrolled hypertension

          -  Frequent hypoglycemia

          -  Women of child-bearing potential
Clinical trial NCT00399438 (phase 2, status: completed)
Conditions: irritable bowel syndrome
ICD codes: K58.2, K58.8, K58.0, K58.1, K58.9
Drugs: placebo, bms-562086
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Female subjects with D-IBS symptoms based on Rome II criteria and the subject's
             responses to the Bowel Disease Questionnaire

        Exclusion Criteria:

          -  Clinically significant prolonged diarrhea with dehydration requiring IV fluid within
             60 days prior to baseline visit
Clinical trial NCT00004106 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    per data monitoring committee given the poor/inadequate accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed mycosis fungoides or Sezary syndrome

               -  Stage IB-IVB disease

               -  Must have failed at least one prior systemic therapy

               -  Generalized erythroderma allowed

          -  Measurable disease and at least one indicator lesion OR evaluable disease for
             erythrodermic patients only

               -  Prior radiotherapy to areas of measurable disease allowed if disease progression
                  is present in the site or if measurable disease is present outside irradiation
                  port

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2 OR

          -  WHO 0-2

        Life expectancy:

          -  At least 3 months

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.2 mg/dL

          -  SGOT or SGPT no greater than 2 times upper limit of normal (ULN)

          -  Alkaline phosphatase no greater than 2 times ULN

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  No New York Heart Association class III or IV heart disease

          -  No clinically significant peripheral venous insufficiency

        Other:

          -  HIV negative

          -  No poorly controlled diabetes mellitus

          -  No acute infection requiring IV antibiotics

          -  No other medical condition that would prevent ingestion or absorption of oral
             medication

          -  No other neoplasm within the past 5 years except curatively treated squamous cell or
             basal cell skin cancer, melanoma in situ, or carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior biologic therapy and recovered

          -  No concurrent growth factors or epoetin alfa

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy and recovered

        Endocrine therapy:

          -  At least 4 weeks since prior topical steroids

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 2 weeks since prior radiotherapy for local control or palliation and
             recovered

        Surgery:

          -  Recovered from prior major surgery

        Other:

          -  No other concurrent investigational drugs
Clinical trial NCT00440388 (phase 2, status: completed)
Conditions: follicular lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: at-101, rituximab
SMILES: [H][C@]1(O)CO[C@]2([H])[C@]([H])(O)CO[C@]12[H], ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed, previously untreated Grade I-II follicular B-cell
             non-Hodgkin's lymphoma (stage I, II, III and IV). Patients may have received radiation
             therapy to one lymph node region; Stage I or II patients must have relapsed after
             prior radiation therapy to be eligible;

          -  Patients with any FLIPI score may participate. Patients with FLIPI scores 3-5 may be
             enrolled with asymptomatic disease, or without worsening disease or disease
             related-symptoms; however patients with FLIPI scores of 0-2 must have evidence of
             worsening disease;

          -  ECOG performance status 0-1;

          -  Measurable disease;

          -  Adequate hematological function as indicated by:

               -  Absolute neutrophil count (ANC) >1,000/µL; +Hemoglobin >8 g/dL (It is acceptable
                  to transfuse PRBC to achieve this criterion);

               -  Platelet count >50 x 109/L.

          -  Adequate hepatic and renal function as indicated by:

               -  Serum creatinine ≤2.0 mg/dL;

               -  Serum albumin ≥2.5 g/dL;

               -  Total bilirubin ≤1.5 x upper limit of normal (ULN);

               -  Serum AST and ALT ≤1.5 x ULN.

          -  Able to swallow and retain oral medication

        Exclusion Criteria:

          -  Patients who have severe lymphoma-related symptoms requiring a rapid response to
             therapy (e.g., requirement for cytoreduction due to advanced disease or organ
             compromise, respiratory compromise because of large effusions or airway obstruction,
             bowel obstruction, ureteral obstruction, and chylous ascites);

          -  Active symptomatic fungal, bacterial and/or viral infection including, but not limited
             to active HIV or viral hepatitis (A, B or C);

          -  History of hepatitis B infection;

          -  Any B-cell, T-cell or transformed lymphoma other than histologically confirmed
             follicular non-Hodgkin's lymphoma;

          -  Central nervous system (CNS) lymphoma, CNS or leptomeningeal involvement by lymphoma
             (treated or in remission), HIV-related lymphoma, or patients with symptoms suggesting
             HIV infection;
Clinical trial NCT01005758 (phase 2, status: unknown status)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide phosphate, hydrocortisone sodium succinate, imatinib mesylate, mercaptopurine, methotrexate, methylprednisolone, pegaspargase, prednisolone, prednisone, vincristine sulfate
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1, S=C1N=CNC2=C1NC=N2, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, N[C@@H](CC1=CN=CN1)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute lymphoblastic leukemia (ALL)

          -  No known mature B-cell ALL*, defined by the presence of surface immunoglobulin, L3
             morphology, t(8;14)(q24;q32), t(8;22), or t(2;8)

               -  Patients with T-cell surface markers and t(8;14)(q24;q11) are eligible NOTE:
                  *Patients with mature B-cell ALL will be removed from the study as soon as that
                  diagnosis is made.

          -  No secondary ALL (i.e., ALL arising after another malignancy)

        PATIENT CHARACTERISTICS:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known HIV positivity (HIV testing is not required)

          -  No comorbid medical condition that would, in the investigator's opinion, make
             participation in this study and adherence to the study guidelines a compromise to the
             study objectives

          -  No active psychiatric or mental illness that would make giving informed consent or
             careful clinical follow-up unlikely

        PRIOR CONCURRENT THERAPY:

          -  No prior anti-leukemic therapy except ≤ 1 week of steroids, emergent radiotherapy to
             the mediastinum, hydroxyurea, or emergent leukapheresis

               -  Patients who have received steroids within the past 7 days are eligible but will
                  not receive steroid prophase therapy on study

          -  No concurrent chronic steroids or anti-metabolite therapy
Clinical trial NCT00014196 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    this study was closed early due to poor accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage IIIB non-small cell lung cancer

               -  Adenocarcinoma

               -  Large cell carcinoma

               -  Squamous cell carcinoma

          -  Pathologically or radiographically documented positive N3 nodes

               -  No positive supraclavicular or scalene lymph nodes with disease extending into
                  the cervical region OR

          -  T4 tumor invading any of the following:

               -  Mediastinum

               -  Heart

               -  Great vessels

               -  Trachea

               -  Esophagus

               -  Vertebral body

               -  Carina

          -  No brain, contralateral chest, liver, or adrenal metastases

          -  No more than 1 parenchymal lesion

          -  No malignant pleural effusions unless they are only visible on CT scan or deemed too
             small to tap

          -  No pericardial effusions

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Zubrod 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine clearance at least 50 mL/min

        Pulmonary:

          -  One of the following:

               -  FEV1 at least 2.0 L

               -  Predicted FEV1 of contralateral lung greater than 800 mL

               -  Predicted post-treatment FEV1 at least 1.0 L

        Other:

          -  No other prior malignancy within the past 5 years except adequately treated basal cell
             or squamous cell skin cancer or carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent growth factors during induction chemoradiotherapy

        Chemotherapy:

          -  No prior chemotherapy for lung cancer

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy for lung cancer

        Surgery:

          -  No prior surgical resection of lung cancer

          -  Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery
             for determining diagnosis, stage, or potential resectability allowed